propiomazine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2298 362-29-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • largon
  • propiomazine
  • propionylpromethazine
  • propiomazine hydrochloride
  • propiomazine HCl
  • Molecular weight: 340.49
  • Formula: C20H24N2OS
  • CLOGP: 4.91
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 23.55
  • ALOGS: -4.69
  • ROTB: 5

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.45 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 33 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 5, 1960 FDA HIKMA MAPLE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional self-injury 5081.84 182.19 924 2987 24763 63460348
Intentional overdose 4498.43 182.19 994 2917 73158 63411953
Depressed level of consciousness 608.26 182.19 202 3709 61876 63423235
Tachycardia 301.58 182.19 146 3765 118010 63367101
Fatigue 226.86 182.19 273 3638 887755 62597356

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional self-injury 1766.89 110.83 328 1243 13443 34941917
Intentional overdose 1502.61 110.83 349 1222 43325 34912035
Depressed level of consciousness 163.41 110.83 64 1507 42777 34912583
Tachycardia 113.04 110.83 61 1510 84711 34870649

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional self-injury 4224.99 108.89 789 2992 31630 79708977
Intentional overdose 3431.38 108.89 815 2966 105145 79635462
Depressed level of consciousness 412.70 108.89 159 3622 96493 79644114
Tachycardia 272.72 108.89 143 3638 177625 79562982
Fatigue 230.14 108.89 248 3533 929479 78811128
Toxicity to various agents 176.65 108.89 151 3630 421389 79319218
Akathisia 169.76 108.89 50 3731 13209 79727398
Mydriasis 119.63 108.89 41 3740 17602 79723005
Somnolence 117.13 108.89 94 3687 238887 79501720

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CM06 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Other hypnotics and sedatives
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drugs
CHEBI has role CHEBI:37956 antihistamines
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:48876 muscarinic antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Local anesthesia indication 386761002
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.19 Basic
pKa2 1.58 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR WOMBAT-PK
D(4) dopamine receptor GPCR WOMBAT-PK
D(1A) dopamine receptor GPCR WOMBAT-PK
Alpha-1B adrenergic receptor GPCR WOMBAT-PK

External reference:

IDSource
4019914 VUID
N0000147999 NUI
D02361 KEGG_DRUG
1240-15-9 SECONDARY_CAS_RN
4018031 VANDF
4019914 VANDF
C0033473 UMLSCUI
CHEBI:8491 CHEBI
CHEMBL252103 ChEMBL_ID
CHEMBL1201210 ChEMBL_ID
CHEMBL1201068 ChEMBL_ID
DB00777 DRUGBANK_ID
C084591 MESH_SUPPLEMENTAL_RECORD_UI
4940 PUBCHEM_CID
7284 IUPHAR_LIGAND_ID
735 INN_ID
242Z0PM79Y UNII
227589 RXNORM
1709 MMSL
5371 MMSL
d00914 MMSL
001488 NDDF
001489 NDDF
373493007 SNOMEDCT_US
41324009 SNOMEDCT_US
65868004 SNOMEDCT_US

Pharmaceutical products:

None